Samsung Biologics discontinues arbitration proceedings against Biogen Samsung and Biogen to operate biosimilar business separately
Translated by Kim So-in 공개 2022-03-25 08:06:54
이 기사는 2022년 03월 25일 08:00 thebell 에 표출된 기사입니다.
Samsung Biologics, the biotech arm of South Korea's Samsung Group, has discontinued the International Chamber of Commerce (ICC) arbitration proceedings against U.S.-based Biogen Therapeutics.The two companies have had a dispute over a non-compete clause signed during their establishment of biosimilar joint venture Samsung Bioepis and started to seek arbitration from the ICC in 2020.
Samsung Biologics said in its report that the company and Biogen stopped the arbitration proceedings filed with the International Court of Arbitration. They reached a settlement in February, following Samsung Biologics’ deal with Biogen in January to buy the U.S. drugmaker's entire stake in Samsung Bioepis.
The arbitration began as the two companies had a disagreement over the non-compete clause in their joint venture agreement to establish Samsung Bioepis in 2011. In 2020, Biogen requested arbitration in the International Chamber of Commerce Court of International Arbitration, seeking interpretation of certain provisions in agreement that the two companies would not engage in independent biosimilar drug business.
With the arbitration case resolved through settlement, Samsung Biologics’ acquisition of Samsung Bioepis is expected to accelerate. Samsung Biologics and Biogen plan to expand their own biosimilar businesses once the Sasmung Bioepis deal is closed in April.
In April 2021, Biogen and China’s Bio-Thera Solutions announced that they entered into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a Phase 3 clinical stage anti-interleukin-6 receptor monoclonal antibody that is a proposed biosimilar referencing ACTEMRA.
Samsung Bioepis is selling five biosimilars, which are Infliximab, Etanercept, Adalimumab, Trastuzumab and Bevacizumab. The company plans to double the number of its biosimilar products on sale to 10 by 2025.
Even after the transaction is closed, Samsung and Biogen will continue to work closely, according to an official of Samsung Biologics. (Reporting by Eun-su Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 나이스평가정보, '아인스미디어·웰컴즈' 인수
- 폴라리스오피스 자회사, 엔비디아 '인셉션 프로그램' 합류
- 소룩스, 美 Mount Sinai 의대와 ‘인지건강 특수조명 공동개발’ 계약
- 세경하이테크, 자회사 세스맷 친환경 확장 '순항'
- [Red & Blue]지오릿에너지, CB 주식전환 물량 출회 부담
- 다보링크, 해외시장 공략·신사업 추진 본격화
- [Red & Blue]포스코 손잡은 '협동로봇' 뉴로메카, 반등 '언제쯤'
- [이사회 모니터]황원경 본부장, 상상인증권 사내이사 합류
- 맥시칸, '지사 역할' 하림유통 합병 '효율성 제고'
- [아난티는 지금]얽히고설킨 지배구조, ESG 'D등급 딱지'